This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
SPARC to receive 55% equity in Tiller Therapeutics
Harnessing advanced data analysis for early detection, prevention and better outcomes
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Subscribe To Our Newsletter & Stay Updated
